Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2002-08-05
2010-02-16
Huynh, Phuong (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S133100, C424S135100, C424S143100, C424S178100, C424S179100, C424S181100, C424S183100, C435S007100, C530S387100, C530S387300, C530S388220, C530S391300, C530S391700
Reexamination Certificate
active
07662374
ABSTRACT:
Antibodies which bind to activated members of the erbB, TNF, and IgSF family of receptors and pharmaceutical compositions comprising the same are disclosed. Peptides and mimetics of erbB, TNF, and IgSF receptors and pharmaceutical compositions comprising the same are also described. Methods of using such antibodies, peptides, and mimetics in tumor therapeutic, prophylactic, imaging and diagnostic applications are disclosed.
REFERENCES:
patent: 4522918 (1985-06-01), Schlom et al.
patent: 5338532 (1994-08-01), Tomalia et al.
patent: 5470571 (1995-11-01), Herlyn et al.
patent: 5637677 (1997-06-01), Greene et al.
patent: 5677171 (1997-10-01), Hudziak et al.
patent: 5705157 (1998-01-01), Greene
patent: 5720954 (1998-02-01), Hudziak et al.
patent: 5725856 (1998-03-01), Hudziak et al.
patent: 5770195 (1998-06-01), Hudziak et al.
patent: 5772997 (1998-06-01), Hudziak et al.
patent: 5821337 (1998-10-01), Carter et al.
patent: 5874400 (1999-02-01), Sundelin et al.
patent: 5955311 (1999-09-01), Rockwell et al.
patent: 5968511 (1999-10-01), Akita et al.
patent: 6100377 (2000-08-01), Greene
patent: 6165464 (2000-12-01), Hudziak et al.
patent: 6252050 (2001-06-01), Ashkenazi et al.
patent: 6342219 (2002-01-01), Thorpe et al.
patent: 6417168 (2002-07-01), Greene et al.
patent: 6627196 (2003-09-01), Baughman et al.
patent: 6949245 (2005-09-01), Sliwkowski
Dermer et al, Bio/Technology 12: 320, 1994.
Gura et al, Science 278: 1041-1042, Nov 1997.
Stryer et al, in Biochemistry, Third edition, W H Freeman Company, New York, pp. 31-33, 1998.
Kuby et al, Immunology, Second edition, pp. 86-96, 1994.
McInnes et al, Biopoly 43: 339-366, 1997.
Kumagai et al, PNAS 98(10): 5526-5531, May 2001.
Bishayee et al, Biochemical Pharmacology 60: 1217-1223, 2000.
Muyldermans et al, J Molecular Recognition 12: 131-140, 1999.
Fendly et al, Cancer Res 50(5): 1550-8, Mar. 1990.
Bishayee et al, Molecular Biology of the Cell 10: 525-536, Mar. 1999.
Jackson et al, Molcular Endocrinology 13: 2175-2188, 1999.
Qian et al, J Biological Chemistry 274(2): 574-583, 1999.
Kumagai et al, Proc Natl Acad Sci 98(10): 5526-5531, May 8, 2001.
Kobrin et al, J Immunology 146: 2017-2020, 1991.
Barrios et al, J Molecular Recognition 17: 332-338, 2004.
Rudikoff et al, Proc Natl Acad Sci USA 79: 1979, 1982.
Scott et al, J biochemistry 266(22): 14300-14305, 1991.
Samata et al, Proc. Natl. Acad. Sci. USA 91:1711, 1994.
Landgraf et al, Biochemistry 39: 8503-8511, 2000.
Witte et al, Cancer and Metastasis Reviews 17: 155-161, 1998.
Yip et al, J Immunology 166: 5271-5278, Apr. 2001.
Fendly et al, Cancer Research 50: 1550-1558, Mar. 1, 1990.
Agus et al, Cancer Cell 2: 127-137, Aug. 2002.
Baselga et al., 1998, “Recombinant Humanized Anti-HER2 Antibody (Herceptin™) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2
euOverexpressing Human Breast Cancer Xenografts”,Cancer Res., 58:2825-2831.
Borgelt et al., 1980, “The Palliation of Brain Metastases: Final Results of the First Two Studies by the Radiation Therapy Oncology Group”,Int. J. Radiat Oncol. Biol. Phys., 6:1-9.
Brown et al., 1994, “Demonstration by Two-Color Flow Cytometry That Tyrosine Kinase Activity Is Required for Down-Modulation of the Oncogenic neu Receptor”,DNA Cell Biol., 13:193-209.
Capone et al., 1984, “Relationship Between Antigen Density and Immunotherapeutic Response Elicited by Monoclonal Antibodies Against Solid Tumors”,JNCI, 72:673-677.
Carter et al., 1992, “Humanization of an anti-p185HER2antibody for human cancer therapy”,PNAS, 89:4285-9.
Christodoulides et al., 1993, “Immunization with synthetic peptides containing epitopes of the class 1 outer-membrane protein ofNeisseria meningitidis: production of bactericidal antibodies on immunization with a cyclic peptide”,J. Genetic Microbiology, 139:1729-1738.
Cohen, 1982, “A Native 170,000 Epidermal Growth Factor Receptor-Kinase Complex from Shed Plasma Membrane Vesicles”,J. Biol. Chem., 258:1523-1531.
Di Blasio et al., 1993, “Noncoded Residues as Building Blocks in the Design of Specific Secondary Structures: Symmetrically Disubstituted Glycines and β-Alanine”,Biopolymers, 33:1037-1049.
Di Fiore et al., 1987, “erbB-2 Is a Potent Oncogene When Overexpressed in NIH/3T3 Cells”,Science, 237:178-182.
Doherty et al., 1999, “TheHER-2
eu, receptor tyrosine kinase gene encodes a secreted autoinhibitor”,PNAS, 96:10869-10874.
Dougall et al., 1994, “Theneu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies”,Oncogene, 2109-23.
Drebin et al., 1984, “Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene”,Nature, 312:545-8.
Drebin et al., 1986, “Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen”,PNAS, 83:9129-9133.
Drebin et al., 1986, “Development of Monoclonal Antibodies Reactive with the Product of theneuOncogene”,Symp Fundam Cancer Res., 38:277-289.
Drebin et al., 1988, “Monoclonal antibodies reactive with distinct domains of theneuoncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo”,Oncogene, 2:273-277.
Ferguson et al., “Extracellular domains drive homo- but not hetero- dimerization of erbB receptors”,EMBO J., 2000, 19:4632-4643.
Fernandez-Pol, 1985, “Epidermal Growth Factor Receptor of A431 Cells”,Biol., Chem., 260:5003-5011.
Hansen et al., 1989, “Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill”,J. Immunol. Methods, 119:203-210.
Heldin, 1995, “Dimerization of Cell Surface Receptors in Signal Transduction”,Cell, 80:213-223.
Hruby, 1993, “Conformational and Topographical Considerations in the Design of Biologically Active Peptides”,Biopolymers, 33:1073-1082.
Jacob et al., 1985, “Priming immunization against cholera toxin andE. coliheat-labile toxin by a cholera toxin short peptide-β-galactosidase hybrid synthesized inE. coli”, EMBO J., 4:3339-3343.
Koprowski et al., 1985, “Expression of the Receptor for Epidermal Growth Factor Correlates with Increased Dosage of Chromosome 7 in malignant Melanoma”,Somatic Cell and Molecular Genetics, 11:297-302.
Kumagai et al., 2001, “The role of distinct p185neuextracellular subdomains for dimerization with the epidermal growth factor (EGF) receptor and EGF-mediated signaling”,PNAS, 98:5526-5531.
Landgraf et al., 2000, “Hegerulin Reverses the Oligomerization of HER3”,Biochemistry, 39:8503-8511.
LeBien et al., 1981, “Use of Monoclonal Antibodies, Morphology, and Cytochemistry to Probe the Cellular Heterogeneity of Acute Leukemia and Lymphoma”,Cancer Res., 41:4776-4780.
Magerstadt, M., 1991, “Antibody-Drug Conjugates, “Chemoimunoconjugates””,Antibody Conjugates and Malignant Disease, CRC Press, Boca Raton, USA, 110-152.
Manning et al., 1993, “Design of cyclic and linear peptide antagonists of vasopressin and oxytocin: current status and future directions”,Reg. Peptides, 45:279-283.
Matsuyama et al., 1992, “A Novel Extracellular Cyclic Lipopeptide Which Promotes Flagellum-Dependent and -Independent Spreading Growth ofSerratia marcescens”, J. Bacteriol., 174:1769-1776.
Murzin et al., 1995, “SCOP: A Structural Classification of Proteins Database for the Investigation of Sequences and Structures”,J. Mol. Biol., 247:536-540.
Nayak et al., 1998, “B Cell Responses to a Peptide Epitope. V. Kinetic Regulation of Repertoire Discrimination and Antibody Optimization for Epitope”,J. Immunol., 161:3510-3519.
O'Rourke et al., 1997, “Trans receptor inhibition of human glioblastoma cells by erbB family ectodomains”,PNAS, 94:3250-55.
Park et al., 2000, “Rationally designed anti-HER2
eu peptide mimetic disables P185HER2
Greene Mark I.
Murali Ramachandran
Richter Mark
Zhang Hongtao
Huynh Phuong
The Trustees of The University of Pennsylvania
Woodcock & Washburn LLP
LandOfFree
Monoclonal antibodies to activated erbB family members and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibodies to activated erbB family members and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibodies to activated erbB family members and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4159167